No insider purchase over the last 90 days. The latest, by Strom Steven, was filed 13 Jul 2022.
Acreage Holdings, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of Acreage Holdings, Inc. in twelve months, the latest record being from 9 December 2024.
Looking back to 2020, when coverage begins, insiders filed 14 purchases and 59 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2023 · cache
25 of 158 declarations
Acreage Holdings, Inc. is a U.S.-based multi-state cannabis operator built around a vertically integrated model that spans cultivation, processing, branded product manufacturing, wholesale distribution, and retail dispensing. In practical terms, the company aims to control the full “seed-to-sale” chain so it can manage product consistency, quality, and the consumer experience across its footprint. Acreage says it was founded in 2011; its SEC filings further indicate that the current corporate structure was formed in 2014 and later redomiciled and renamed Acreage Holdings, Inc. in 2018. ([acreageholdings.com](https://www.acreageholdings.com/about-us/?utm_source=openai))
From a market perspective, Acreage has been associated with North American cannabis listings and has cited Canadian/U.S. market venues such as the CSE and OTCQX in company disclosures and announcements. For U.S. equity investors, the more important takeaway is that Acreage has been a U.S.-focused issuer with significant SEC reporting history, which places it within the universe of U.S.-linked public equities followed for corporate actions, insider activity, and regulatory developments. Given the cannabis industry’s structure in the United States, the stock has also been exposed to elevated legal and policy risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1762359/000176235924000023/acrg-20231231.htm?utm_source=openai))
Acreage’s core business lines are cultivation, processing, retail, and consumer brands. The company markets products under brands such as The Botanist, positioned around a trusted, premium-yet-accessible consumer experience, and Superflux, which focuses on concentrates, vapes, and premium flower. In its latest annual report available through the SEC, Acreage stated that it operated in eight states and owned and operated 23 dispensaries, with a footprint including Ohio, Maine, New York, New Jersey, Connecticut, Massachusetts, and Illinois. That geographic spread gives it exposure to both medical and adult-use markets, depending on state rules. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1762359/000176235924000023/acrg-20231231.htm?utm_source=openai))
Competitive positioning is typical of a U.S. multi-state operator: fragmented market structure, local licensing barriers, and intense competition for retail locations, cultivation capacity, and shelf space. Acreage’s relative strengths have historically been its vertical integration, brand development, and ability to tailor products to state-specific demand. The company emphasizes operational excellence, product consistency, and a broad portfolio designed to serve new and existing cannabis consumers. ([acreageholdings.com](https://www.acreageholdings.com/?utm_source=openai))
Recent corporate developments are especially important. In June 2024, Acreage announced corporate transactions that included the exercise of the call option to acquire its fixed shares, effectively moving the Canopy USA transaction forward. In December 2024, Acreage confirmed the completion of Canopy USA’s acquisition of Acreage. Prior to that closing, management also highlighted a growth push in key states such as New Jersey, Illinois, Connecticut, and Ohio. For investors, Acreage is best understood as a cannabis operating platform that became part of a broader consolidation story, while still reflecting the underlying regulatory complexity of the U.S. cannabis market. ([globenewswire.com](https://www.globenewswire.com/news-release/2024/06/04/2893023/0/en/acreage-announces-corporate-transactions.html?utm_source=openai))
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2023 | 223.4 m USD | -69.1 m USD | -0.61 USD | 10-K |
| Dec 2022 | 237.1 m USD | -139.9 m USD | -1.28 USD | 10-K |
| Dec 2021 | 188.9 m USD | -63.0 m USD | -0.60 USD | 10-K |
| Dec 2020 | 114.5 m USD | -286.6 m USD | -2.92 USD | 10-K |
| Dec 2019 | 74.1 m USD | -150.3 m USD | -1.74 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.